X0508 4 2024-05-13 false 0001560241 G1 Therapeutics, Inc. GTHX 0001967910 Umstead John W. V 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 false true false false Chief Financial Officer false Common Stock 2024-05-13 4 S false 8151.00 4.7888 D 153245.00 D The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. The price represents the weighted average price with a low of $4.62 and a high of $4.98. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents (i) 18,770 shares of common stock; (ii) 425 RSUs from award granted on January 4, 2021; (iii) 2,000 RSUs from award granted on January 3, 2022; (iv) 2,250 RSUs from award granted on January 3, 2023; (v) 37,500 RSUs from award granted on March 15, 2023; (vi) 17,500 RSUs from award granted on May 10, 2023; (vii) 37,300 RSU's granted on January 3, 2024; and (viii) 37,500 RSUs granted on March 20, 2024. /s / Monica Roberts Thomas, attorney-in-fact 2024-05-15